Lindahl was legal counsel to Senzime AB (publ) in connection with the company’s rights issue which was resolved by the board of directors on 23 January 2023 and approved at an extraordinary general meeting on 16 February 2023. The purpose of the rights issue is to enable the company’s continued growth journey. Through the rights issue, Senzime will receive proceeds of approximately SEK 91.9 million before deduction of transaction costs.
Senzime’s share is listed on Nasdaq Stockholm Main Market and the company develops, manufactures and markets CE- and FDA-cleared patient monitoring systems with the vision of a world without anesthesia- and respiratory-related complications.
Lindahl’s team consisted of Helena Lindbäck, Michaela Larsson, Erika Svensson and Mattias Prage.